Press release

Organ Transplant-Focused TransMedics Stock Soars, Solid Q3 Performance In Focus

TransMedics Group Inc (NASDAQ: TMDX) reported Q3 revenues of $66.4 million, a 159% Y/Y increase, beating the consensus of $49.19 million.

The increase was due primarily to greater utilization of the company's NOP across all three OCS products and the addition of logistics and aviation revenue. 

Revenue from the new, transplant-related aviation and logistics offerings was $2.1 million. Additionally, total revenue ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner
Trending

More to read